National Institute for Health and Welfare, Division of Health and Social Services, P.O. Box 30, 00271 Helsinki, Finland.
Soc Sci Med. 2010 Apr;70(8):1171-5. doi: 10.1016/j.socscimed.2010.01.005. Epub 2010 Feb 12.
The aim of the study was to investigate the co-operation between patient organizations and the drug industry in Finland prior to critical discussions on the topic. The data were gathered by a questionnaire survey of 85 patient organisations (response rate 65%, n = 55) and 20 drug firms (response rate 100%) in 2003, and by interviewing 13 organisations and surveying their web-pages and other documents in 2004. In the surveys, half of the patient organisations and 80% of the drug firms considered co-operation important. Most (71%) organisations reported financial support from the drug industry. Most organisations and drug firms had experienced problems. Common problems for organisations were too little or too unpredictable support from industry, and threats to independence and objectivity. Drug firms frequently mentioned unclear rules of co-operation. The patient organisation interviews exhibited similar themes and findings to those found in the surveys, revealing the complexity and importance of co-operation in organisation activities, and the variation between organisations. This case study from Finland showed that co-operation between patient organizations and the drug industry was common, many-sided and not usually transparent. The close connections between patient organizations and commercial companies, particularly drug firms, raise several policy issues and the need for action.
本研究旨在探讨芬兰在对该主题进行批判性讨论之前,患者组织与制药业之间的合作情况。研究数据来自于 2003 年对 85 家患者组织(回应率为 65%,n=55)和 20 家制药公司(回应率为 100%)的问卷调查,以及 2004 年对 13 家组织的访谈和对其网页及其他文件的调查。在调查中,一半的患者组织和 80%的制药公司认为合作很重要。大多数(71%)组织报告了制药业的财政支持。大多数组织和制药公司都遇到了问题。组织常见的问题是来自行业的支持太少或不可预测,以及对独立性和客观性的威胁。制药公司经常提到合作规则不明确。患者组织的访谈展示了与调查中发现的类似主题和发现,揭示了合作在组织活动中的复杂性和重要性,以及组织之间的差异。这项来自芬兰的案例研究表明,患者组织与制药业之间的合作是常见的、多方面的,而且通常不透明。患者组织与商业公司,特别是制药公司之间的密切联系引发了一些政策问题和行动需求。